Aura GT System
Fast, decisive, low-volume AAV characterization for gene therapy development workflows
Adeno-associated viruses (AAVs) have revolutionized gene therapy product development. With limited material available, allocating valuable samples for aggregate testing may have seemed impractical—until now.
Aura GT System is the first and only system designed to detect, count, and characterize AAV particles with just 5 µL. Combining backgrounded membrane imaging (BMI) with fluorescence membrane microscopy (FMM) dual-channel technology, confident decisions can be made earlier—one step closer to success.
Analyze small volumes. Only 5 µL of sample is needed, allowing particle characterization in early phase development.
Characterize and identify viral vectors. Aura GT System distinguishes between capsid and non-capsid aggregates and enables you to confirm whether DNA leakage is the root cause of aggregation straight from the box.
Gain deeper gene therapy understanding. Gain insight with Aura GT System’s duo of BMI and FMM, which distinguish and characterize different serotypes for aggregation and product features for deeper understanding of gene therapy – without tedious, labor-intensive assays.
Aura GT System
Specifications
|
Imaging area |
24.6 mm2 |
|
Optics |
4x objective |
|
Minimum volume |
5 µL (assay dependent) |
|
Resolution |
1.0 pixel/µm |
|
Detectable size range |
Range from >1 µm (ECD) to <5 mm (ECD) |
|
BMI read time |
1 minute/sample |
|
FMM read time |
2 FL channels, 30 seconds/sample |
|
Software |
Particle Vue 4.x all-in-one Software suite (image capture and analysis) |
Overview
- Characterize AAV, lentivirus, and other viral vectors across key applications like aggregation and stability.
- Detect, count, and characterize AAV particles with just 5 µL of sample. Identify capsid and DNA aggregates in your gene therapy sample with confidence.
- Make direct comparisons between different formulations, AAV serotypes, storage conditions, and lots.
- Detect and count particles from 1 µm up to 5 mm.
- Save time with measurements under one minute per sample.
Recommended Use: For viral vector and AAV aggregation and stability studies in gene therapy development.
Easily quantify and identify AAV particles
AAVs are known to form large, subvisible aggregates that cannot be easily predicted or quantified, making it difficult to assess their impact on patients. To make things even more convoluted, unstable AAVs can aggregate in unpredictable shapes and forms. The Aura GT System offers an easier way to identify and characterize AAV aggregates. With Aura GT System, you can characterize your AAV particles with the lowest volume requirements, highest throughput, and gain insight into their stability.
Identify root cause and characterize AAV particles at low volume
Researchers have long sought to identify the root cause of unstable AAV particles, a challenge compounded by legacy systems that lack the ability to perform low-volume SVP analysis or assess DNA content. The Aura GT System overcomes this hurdle in a single 5 µL assay.
By leveraging fluorescent dyes such as thioflavin T (ThT) and SYBR™ Gold, you can confidently identify capsid aggregates and DNA in your gene therapy sample using FMM. This enables more informed AAV candidate selection and helps uncover the root causes of aggregation at the very start of your development process.
Obtain actionable insights in hours, not months
Get your gene therapy products to market even faster with Aura GT System. Instead of waiting months for results, the Aura GT System’s 96-well particle screening assay delivers actionable insights in just a few hours. With Aura GT System, you can make direct comparisons across formulations, AAV serotypes, stability profiles, storage conditions, and production lots.
Resources
Documents
What do you want to do?
Frequently Asked Questions
What is AAV characterization?
AAV (adeno-associated virus) characterization involves assessing the properties and quality of AAV vectors used in gene therapy applications. This process includes evaluating parameters such as vector purity, titer, potency, stability, and integrity of the viral genome. AAV characterization ensures that the vectors meet specific quality standards and are suitable for gene therapy.
What is AAV titration?
AAV titration determines the concentration (titer) of AAV vectors in a sample. Accurate titration is essential for gene therapy applications to ensure the correct dosage of vectors to patients. Various methods, such as quantitative PCR (qPCR), droplet digital PCR (ddPCR), or enzyme-linked immunosorbent assay (ELISA), can be used for AAV titration.
